Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Chemo + SBRT in Oligometastatic NSCLC
NCT04255836Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival up to 2 years. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04255836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255836.